New tuberculosis drugs in development

Area of Science:

• Infectious Diseases
• Drug Development
• Global Health

Background:

• Tuberculosis (TB) remains a critical global health emergency, causing millions of deaths and infections yearly, particularly in developing nations.
• The TB epidemic is accelerating in Africa and Asia, exacerbated by the HIV epidemic and increasing resistance to standard drugs like isoniazid and rifampicin.
• The pharmaceutical industry's withdrawal from TB drug development, citing market non-profitability, has created a critical gap in addressing this persistent disease.

Purpose of the Study:

• To highlight the urgent need for novel drug classes to combat tuberculosis.
• To underscore the challenges posed by multidrug-resistant and extensively drug-resistant TB strains.
• To emphasize the shift towards public sector and research-driven initiatives in TB drug discovery.

Main Methods:

• Review of historical TB drug development trends and current treatment landscape.
• Analysis of factors contributing to the rise of drug-resistant tuberculosis.
• Examination of the role of public health initiatives, research funding, and partnerships in advancing TB control.

Main Results:

• No new classes of TB drugs have been introduced in the last 50 years.
• Emerging resistance patterns are rendering current antibiotics ineffective against certain mycobacteria strains.
• Public and research sectors are actively developing new chemical entities and control strategies, but advanced development and clinical trials remain under-resourced.

Conclusions:

• There is a critical unmet need for new tuberculosis drugs due to widespread resistance and lack of industry investment.
• Continued collaboration between public sectors, researchers, funding agencies, and philanthropic donors is essential for TB drug development.
• Addressing advanced preclinical and Phase III clinical trial gaps is crucial for bringing new TB therapies to patients.